Litak® (Cladribine) – 2 mg/ml
Cladribine is an antineoplastic agent of the following pharmacotherapeutic group: antineoplastic agents, antimetabolites, purine analogues (ATC-Code: L01BB04). The selective toxicity cladribine towards certain normal and malignant lymphocyte and monocyte populations is based on the relative activities of deoxycytidine kinase, deoxynucleotidase and adenosine deaminase.
Share Now
Additional Information
| Name | Litak® |
| Description | Cladribine is an antineoplastic agent of the following pharmacotherapeutic group: antineoplastic agents, antimetabolites, purine analogues (ATC-Code: L01BB04). The selective toxicity cladribine towards certain normal and malignant lymphocyte and monocyte populations is based on the relative activities of deoxycytidine kinase, deoxynucleotidase and adenosine deaminase. It is postulated that cells with high deoxycytidine kinase and low deoxynucleotidase activities will be selectively killed by cladribine as toxic deoxynucleotides accumulate intracellularly. Cells containing high concentrations of deoxynucleotides are unable to properly repair single-strand DNA breaks. |
| Active Ingredient | Cladribine |
| Indication | Litak® is a solution for injection that contains the active substance cladribine to treat rare forms of leukemia or lymphoma. |
| Strengths | 2 mg/ml |
| Business Partner | Lipomed |
| Origin | Switzerland |
Related Products
Disclaimer
Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the respective local health authority or contracted by the MAH to supply to the end users on a named patient basis. Some products such as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.
